A novel management program for hypertension.
In this article, we describe a comprehensive management program for hypertension (HTN), based on the experience of leading cardiovascular centers in China. This comprehensive approach, adhering to a number of core principles, includes diagnosis and therapeutic interventions. Therapeutic management includes lifestyle changes, risk factor management and pharmacological intervention and should allow reliable lowering blood pressure (BP). Additional paragraphs discuss the relationship between paroxysmal atrial fibrillation (PAF), and HTN.
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Chun-Song
CS
Hu
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Ya-Ling
YL
Han
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Jun-Bo
JB
Ge
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Qing-Hua
QH
Wu
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Yan-Na
YN
Liu
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Chang-Sheng
CS
Ma
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Tengiz
T
Tkebuchava
1 Department of Cardiology, Nanchang University, Nanchang 330006, China ; 2 Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110840, China ; 3 Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, China ; 4 Department of Cardiology, Center for Atrial Fibrillation, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China ; 5 Boston TransTec, LLC, MA 02459, USA ; 6 Cardiovascular Center, Peking University People's Hospital, Beijing 100044, China.
Da-Yi
DY
Hu
Hypertension (HTN); paroxysmal atrial fibrillation (PAF); treatment